European Commission logo
English English
CORDIS - EU research results

Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19

Project description

New test tells COVID-19 patients if they can go home

Assessing the risk factors for severe COVID-19 illness is vital for healthcare providers and hospitals. While this disease is new, it is evident that it can affect anyone. However, the disease can cause symptoms ranging from mild to severe. The EU-funded RISCinCOVID project bring to market the suPARnostic test, which has been developed by Danish company ViroGates. It’s a prognostic inflammatory biomarker that reflects the level of activation of the human immune system. A low suPAR level indicates a good prognosis and supports the decision to discharge the patient. According to ViroGates, their test can identify 22 % more patients that can be sent home without hospitalisation and avoid unnecessary treatments and readmissions.


Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19

To optimize hospital resources, it is necessary to test which patients that can be sent home (mild outcome of infection) and which patients that should be admitted to hospital (high risk patients).

This will deliver on the tasks: 1) Identify patients that can safely cope with the infection at home and 2) Identify high risk patients early in the disease and 3) Select high-risk patients that may benefit of therapy.
But how can we identify low- or high-risk patients?

The suPARnostic test developed by ViroGates and CE/IVD approved for clinical use is highly prognostic marker for 30-day mortality.
Some hospitals have suPAR in routine clinical assessment of patient risk, and preliminary data support that suPAR levels can triage whether patients with COVID-19 will have a mild or a severe outcome of COVID-19 and thereby select which patients that could be discharged or admitted.

We aim to transfer manufacturing, upscale and implement the suPARnostic technology across hospitals in Europe to improve the risk stratification of COVID-19 patients and optimize hospital resources. We furthermore provide a test method that can identify high-risk patients that may benefit from experimental therapeutic interventions that may impact on outcome. The identification of patients in high risk of mortality (patients with high suPAR) provide a possibility to intervene.

Call for proposal


See other projects for this call

Sub call


Funding Scheme

SME - SME instrument


Net EU contribution
€ 884 990,00

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Danmark Hovedstaden Nordsjælland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 1 470 057,00